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Abstract. 
 
Myf5 is the earliest-known muscle-specific 
factor to be expressed in vivo and its expression is asso-
ciated with determination of the myoblast lineage. In 
C2 cells, we show by immunocytolocalization that Myf5 
disappears rapidly from cells in which the differentia-
tion program has been initiated. In proliferating myo-
blasts, the levels of Myf5 and MyoD detected from cell 
to cell are very heterogeneous. We find that some of 
the heterogeneity of Myf5 expression arises from a 
posttranscriptional regulation of Myf5 by the cell cycle. 
Immunoblotting of extracts from synchronized cultures 
reveals that Myf5 undergoes periodic fluctuations dur-
ing the cell cycle and is absent from cells blocked early 
in mitosis by use of nocodazole. The disappearance of 
Myf5 from mitotic cells involves proteolytic degrada-
tion of a phosphorylated form of Myf5 specific to this 
phase of the cell cycle. In contrast, MyoD levels are not 
depleted in mitotic C2 cells. The mitotic destruction of 
Myf5 is the first example of a transcription factor show-
ing cell cycle–regulated degradation. These results may 
be significant in view of the possible role of Myf5 in 
maintaining the determination of proliferating cells and 
in timing the onset of differentiation.
 
T
 
erminal 
 
differentiation of muscle cells, both in vivo
and ex vivo, is dependent upon the functions of the
myogenic regulatory factors (MRFs)
 
1
 
 (for review
see Yun and Wold, 1996). These include factors of the ba-
sic helix-loop-helix family MyoD, Myf5, and myogenin
(Davis et al., 1987; Braun et al., 1989
 
b
 
; Wright et al., 1989).
Expression of any one of these MRFs is sufficient to con-
vert a variety of cell types to the myogenic differentiation
pathway (for review see Weintraub et al., 1991; Olson and
Klein, 1994).
The mechanisms by which MyoD induces myogenesis
(for review see Lassar et al., 1994; Molkentin and Olson,
1996) involve both the activation of muscle-specific gene
expression and withdrawal from the cell cycle (Crescenzi
et al., 1990; Sorrentino et al., 1990). MyoD-induced cell cy-
cle arrest in G1 requires the retinoblastoma protein or its
homologue p107 (Gu et al., 1993; Schneider et al., 1994;
Zacksenhaus et al., 1996), and is maintained through accu-
mulation of the cyclin-dependent kinase (cdk) inhibitor
p21 (Guo et al., 1995; Halevy et al., 1995). The functions of
MyoD are repressed in proliferating myoblasts. At least
one such mechanism is mediated by cyclin D1 (Rao et al.,
1994; Skapek et al., 1995, 1996).
MyoD and Myf5 are often classed as “determination”
factors since they are expressed in proliferating myoblasts,
in contrast to myogenin expression, which coincides with
cell cycle arrest, and MRF4, which is found only in mature
myotubes (Braun et al., 1989
 
a
 
; Montarras et al., 1991; An-
drés and Walsh, 1996). The functions of Myf5 are poorly
understood. Myf5 is the earliest of the factors expressed in
the mouse embryo and its expression is transient (between
8 and 12 d post coitum [p.c.]) (Ott et al., 1991). Downregu-
lation of Myf5 transcripts precedes full muscle differentia-
tion both in vivo (Ott et al., 1991) and ex vivo (Montarras
et al., 1991). This transient expression of Myf5 is required
to maintain the determined state of certain muscle precur-
sor cells, since these abandon the myogenic lineage in
 
myf5
 
2
 
/
 
2
 
 embryos (Tajbakhsh et al., 1996). The phenotypes
of mice mutated in Myf5 and MyoD indicate that these
two factors are capable of some functional redundancy
(Braun et al., 1992; Rudnicki et al., 1992, 1993). It has been
suggested that MyoD and Myf5 could determine parallel
and equivalent myogenic lineages (Braun and Arnold,
1996).
Muscle cell lines such as C2 (Yaffé and Saxel, 1977; Pin-
set et al., 1988) provide strong models for the study of
myoblasts and their terminal differentiation into multinu-
cleated myotubes. In their proliferative state these cells ex-
press both MyoD and Myf5 (Braun et al., 1989
 
a
 
; Montar-
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Abbreviations used in this paper
 
: ALLN, 
 
N
 
-acetyl-Leu-Leu-norleucinal;
cdk, cyclin-dependent kinase; IGF, insulin-like growth factor; MRF, myo-
genic regulatory factors; RIPA, radioimmunoprecipitation assay.
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ras et al., 1991). To further clarify the role of Myf5 in
determination and differentiation and its relationship to
the proliferative state of myoblasts, we have examined the
expression of Myf5 protein in C2 cells and in a C2-derived
cell line incapable of autonomous differentiation (Montar-
ras et al., 1996). We find that Myf5 is downregulated in
cells undergoing differentiation and that in proliferative cells,
Myf5 levels are strongly regulated by cell cycle–associated
events that include the destruction of this factor at mitosis.
 
Materials and Methods
 
C2 Cell Culture and Differentiation
 
C2.7 and anti–insulin-like growth factor II (anti-IGFII) C2 cells have been
previously described (Pinset et al., 1988; Montarras et al., 1996). Both cell
lines are cultured in a 1:1 (vol/vol) mixture of MCDB 202 medium and
DME (both from BICEF, l’ Aigle, France) containing 20% (vol/vol) FCS
(Jacques Boy, Reims, France). C2.7 cells are maintained in a proliferative
state by replating at low cell density. To obtain autonomously differentiat-
ing C2.7 cells, these were plated at a density of either 2.5 
 
3
 
 10
 
3
 
 cells/cm
 
2
 
(see Figs. 1 and 2 
 
B
 
) or 2.5 
 
3
 
 10
 
2
 
 cells/cm
 
2
 
 (see Fig. 2 
 
A
 
), and the cultures
were allowed to age, without change of medium, for 6 d. Cells were pre-
pared for synchronization or preparation of mitotic cell extracts (see be-
low) by plating at an initial density of 2.5 
 
3
 
 10
 
3
 
 cells/cm
 
2
 
 and 48 h of prolif-
eration.
 
Synchronization of Anti-IGFII C2 Myoblasts, and
Flow Cytometry
 
Synchronized populations of cells were obtained as described in figure
legends. Aphidicolin (stored as 1 mg/ml stock in H
 
2
 
O), nocodazole (1 mg/
ml in DMSO), and 
 
N
 
-acetyl-Leu-Leu-norleucinal (ALLN; 100 mM in
DMSO) were obtained from Sigma Chemical Co. (St. Louis, MO).
Mitotic shake-off fractions were prepared by mechanical detachment of
nocodazole-arrested cells. These were washed in PBS and used to make
extracts, as was the adherent fraction of cells remaining attached to the
culture dishes (see below).
In preparation for flow cytometric analysis of DNA content, synchro-
nized cells (2–5 
 
3
 
 10
 
6
 
) were harvested by trypsinization, washed twice in
cold PBS, and then fixed by resuspension in cold 70% ethanol and incuba-
tion at 4
 
8
 
C overnight. Cells were then washed once in PBS and resus-
pended in 1 ml PBS, to which were added 50 
 
m
 
g RNase and propidium io-
dide to a final concentration of 10 
 
m
 
M. Propidium iodide fluorescence of
20,000 cells per sample was measured using a FACStar
 
®
 
 Plus cytometer
(Becton and Dickinson, Co., Mountain View, CA).
 
Indirect Immunofluorescence
 
Immunofluorescence was performed on cells grown on 35-mm plastic tis-
sue culture plates (Falcon Plastics, Cockeysville, MD). PBS was used to
wash cells extensively before fixation and after each step of the procedure
described, which was carried out at room temperature. Cells were fixed in
4% (wt/vol) paraformaldehyde in PBS for 10 min, and then neutralized
for 10 min in 50 mM NH
 
4
 
Cl in PBS. Permeabilization of cells was
achieved with 0.2% Triton X-100 in PBS. Immunodetection involved
three consecutive incubations with antibodies diluted in PBS containing
0.2% (wt/vol) gelatin (Merck, Darmstadt, Germany): (
 
a
 
) 1-h incubation
with primary antibodies. These are described in detail below. One rabbit
and one mouse antibody were used simultaneously for the codetections
shown in Figs. 1 and 2. (
 
b
 
) 30-min incubation with secondary antibodies:
goat anti–mouse immunoglobulins coupled to Texas red (1/100 dilution;
Amersham International, Little Chalfont, UK), and goat anti–rabbit im-
munoglobulins coupled with biotin (1/200; Sigma Chemical Co.) (Fig. 1
 
A
 
); or goat anti–rabbit coupled to FITC (1/200; Sigma Chemical Co.), and
goat anti–mouse coupled with biotin (1/200; Sigma Chemical Co.) (Figs. 1
 
B
 
 and 2); or goat anti–rabbit antibody coupled with biotin (1/200; Sigma
Chemical Co.) alone (see Fig. 3). (
 
c
 
) 20-min incubation with FITC-cou-
pled streptavidin (FITC-Extravidin; 1/200; Sigma Chemical Co.) (Figs. 1 
 
A
 
and 3); or with Texas red–coupled streptavidin (1/100; Amersham Inter-
national) (Figs. 1 
 
B
 
 and 2). Cells were mounted in Mowiol (Calbiochem-
Novabiochem, La Jolla, CA) under glass coverslips.
 
Preparation of Protein Extracts and Western Blotting
 
Protein extracts were made by chilling plates on ice and washing with cold
PBS followed by lysis into radioimmunoprecipitation assay (RIPA) buffer
(50 mM NaCl, 25 mM Tris 8.2, 0.5% NP-40, 0.5% Na deoxycholate, 0.1%
SDS, 1 mM DTT containing protease inhibitors as described in Mellits et al.
[1993]). Lysates were collected, sheared by six passages through a 25-
gauge needle, and debris removed by centrifugation at 12,000 
 
g
 
 at 4
 
8
 
C.
Approximately 20 
 
m
 
g extract per sample was analyzed by 9% SDS-
PAGE, and transferred to nitrocellulose Hybond-C Extra filters (Amer-
sham International) using a trans-blot semi-dry electrophoretic transfer
cell (Bio-Rad Laboratories, Hercules, CA). Homogeneity of loading and
transfer were checked by staining filters with Ponceau S dye (Sigma Chem-
ical Co.). Filters were blocked for nonspecific binding by incubation for 2 h
at room temperature in PBS containing 0.1% Tween-20 with 5% (wt/vol)
powdered skim milk, which was also used to dilute all antibodies. Incuba-
tions with primary antibodies (described below) were for 90 min at room
temperature. Filters were washed extensively in Tween-20–PBS before
secondary incubation for 30 min with goat polyclonal antibodies against
either rabbit or mouse immunoglobulins, coupled to horseradish peroxi-
dase (diluted 1/10
 
4
 
; Sigma Chemical Co.). Filters were washed and treated
with ECL Western blotting detection reagents (Amersham International).
Where filters were probed successively with several antibodies (see Fig.
4), previous antibodies were removed by stripping in PBS containing 2%
SDS and 100 mM 
 
b
 
-mercaptomethanol at 50
 
8
 
C for 20 min, after which the
filters were washed and reblocked.
 
Antibodies
 
The Myf5 antibody used to generate Fig. 3 is a polyclonal rabbit serum
raised against the COOH-terminal peptide (237–255). Antibodies raised
against the Myf5 NH
 
2
 
-terminal and COOH-terminal domains and used for
all other figures in this paper were the gift of Dr. M. Primig (Unité de
Génétique Moléculaire du Développement, Pasteur Institute, Paris, France).
The NH
 
2
 
-terminal antibody used in Figs. 1 and 2 and the COOH-terminal
antibody in Fig. 5, had been affinity purified. All Myf5 antibodies were
used at 1/1,000 dilution for indirect immunofluorescence and 1/300 in Western
blotting. Myogenin was detected using mouse monoclonal F5D (at 1/100
dilution), provided by Dr. W. Wright (University of Texas, Dallas, TX).
Mouse monoclonal antibodies were used to detect MyoD (NCL-MyoD1;
Novocastra, Burlingame, CA), troponin T (T6277; Sigma Chemical Co.),
and cJun (J31920; Transduction Laboratories, Lexington, KY) at concen-
trations recommended by the suppliers. Sp1 was detected with a rabbit
polyclonal antibody (sc-059; Santa Cruz Biotechnology, Santa Cruz, CA).
 
Preparation of RNA and Northern Blotting
 
Preparation, electrophoresis, and blotting of total RNA from synchro-
nized cell cultures was as previously described (Pinset et al., 1988). 10 
 
m
 
g
of each sample was analyzed. Homogeneity of loading was monitored by
staining of gels with ethidium bromide before transfer, and measured by
probing for the ribosomal protein S26 (Vincent et al., 1993). The Myf5
probe used has been described in Montarras et al. (1996).
 
Results
 
Myf5 Is Absent from Myoblasts at the
Onset of Differentiation
 
The recent availability of antibodies against Myf5 (Primig,
M., manuscript in preparation; and Auradé et al., 1997)
enabled us to investigate the expression of this factor dur-
ing the autonomous differentiation of C2 myoblasts (Pin-
set et al., 1988). These antibodies specifically recognize
Myf5 by immunocytochemical techniques and show no
cross-reaction with other MRFs in immunoblot analyses
(not shown). Previous studies have shown that the level of
Myf5 mRNA in various myogenic cell lines is downregu-
lated under conditions favorable to differentiation (Mon-
tarras et al., 1991, 1993; Mangiacapra et al., 1992). Code-
tection by indirect immunofluorescence of Myf5 with 
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troponin T, a marker for myogenic differentiation (Pinset
and Montarras, 1994) shows that Myf5 protein is not de-
tected in cells that express troponin T (Fig. 1 
 
A
 
). This finding
is in agreement with previous expression data, and sug-
gests that the Myf5 mRNA detected in extracts from myo-
tube cultures (Montarras et al., 1991) reflects the presence of
residual myoblasts. The half-life of Myf5 protein is very
short—not 
 
.
 
30 min in C2 cells (Lindon, C., unpublished
observations)—thus the disappearance of the protein must
follow closely the downregulation of the Myf5 message.
To establish more precisely the timing of the downregu-
lation of Myf5, we examined its codetection with myoge-
nin (Fig. 1 
 
B
 
). Myogenin is the earliest known marker for
myoblasts committed to the differentiation pathway (Wright
et al., 1989), and in a recent study has been shown to be ex-
pressed before the establishment of the postmitotic state
(Andrés and Walsh, 1996). We find that, in general, detec-
tion of Myf5 in myogenin-positive nuclei is reduced com-
pared to the levels detected in myogenin-negative nuclei.
We propose that the downregulation of Myf5 occurs either
before or simultaneously with the appearance of myoge-
nin in these cells. The disappearance of Myf5 protein is
thus a very early event in the exit of C2 myoblasts from a
determined state to one in which they are committed to
differentiate.
Fig. 2 
 
A
 
 shows both Myf5 and MyoD expressed in prolif-
erating C2 myoblasts. The levels of these factors in the myo-
blast population are heterogeneous, but there is no clear
relationship between the relative levels of the two factors
in these cells. In a differentiating culture, by contrast, the
codetection of Myf5 with MyoD is much reduced. The myo-
blasts resolve almost completely into two populations dis-
tinguished by the predominant expression of either one or
the other of the two factors (Fig. 2 
 
B
 
). At this stage in the
differentiation of the culture, the MyoD-expressing popu-
lation of cells has undergone some fusion into myotubes,
whereas the Myf5-expressing cells have mostly failed to dif-
ferentiate.
Thus the pattern of expression in differentiating myo-
blasts of the determination factor Myf5 contrasts strongly
with that of MyoD. Whereas MyoD is upregulated in dif-
ferentiating cells, Myf5 is downregulated early in differen-
tiation. Our data suggest that this downregulation of Myf5
may coincide with the commitment of myoblasts to the dif-
ferentiation pathway.
 
Myf5 Protein Levels Are Regulated by the Cell Cycle
 
The considerable heterogeneity of the levels of Myf5 and
MyoD detected in proliferating myoblasts led us to exam-
ine the possibility of cell cycle–dependent effects on the
expression of these factors. We chose to study Myf5 ex-
pression in a C2-derived cell line, in which expression of
IGFII and MyoD are eliminated by the expression of an
antisense-IGFII construct (anti-IGFII C2 myoblasts; Mon-
tarras et al., 1996). Since these myoblasts are unable to dif-
ferentiate autonomously (requiring treatment with IGFs
to do so), they can be synchronized in G0 and G1 phases
of the cell cycle without undergoing terminal differentia-
tion. Previous detection of Myf5 in these cells by immuno-
fluorescence has shown that the basal level of expression is
as heterogeneous as in the parental C2 cells (Auradé et al.,
1997).
We investigated the cell cycle–associated changes in the
level of Myf5 by synchronization of myoblasts through the
cell cycle (Figs. 3 and 4). This was achieved by sequential
use of serum deprivation, aphidicolin, and nocodazole, to
arrest the myoblasts in G0, at the G1/S boundary, and in
Figure 1. Downregulation of Myf5
is a very early event in myogenic
differentiation. C2.7 cells were cul-
tured under conditions favorable to
differentiation for 6 d and treated
for indirect immunofluorescence.
Cells were stained for Myf5 (red)
and troponin T (green) (A), or
Myf5 (green) and myogenin (red)
(B). The resulting images were pre-
pared by confocal microscopy to
give a better estimation of coexpres-
sion of the markers examined. Bars,
10 mm. 
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early M, respectively. Aphidicolin is an inhibitor of DNA
polymerase 
 
a
 
 (Spadari et al., 1982), and nocodazole is an
inhibitor of microtubule depolymerization used at weak
doses to specifically block the progress of cells through
metaphase (Rieder and Palazzo, 1992). The effects of both
cell cycle blockers are fully reversible.
Our initial observations are illustrated in Fig. 3 and re-
veal that synchronization of myoblast populations affects
the levels of Myf5 detected. We find that Myf5 levels are
generally lower in cultures synchronized in G1 (Fig. 3,
 
middle
 
), than in those progressing through S phase (Fig. 3,
 
bottom
 
). In serum-deprived cells (G0; Fig. 3, 
 
top
 
), Myf5 is
strongly heterogeneous, thus in noncycling cells there are
clearly additional mechanisms that generate variations in
the expression of Myf5. It was not possible to investigate
the presence of Myf5 in mitotic cells by immunofluores-
cence because of nonspecific staining of these cells (not
shown).
To investigate in a more quantitative fashion the cell cycle
regulation of Myf5, we prepared extracts from synchro-
nized cell populations for Northern and Western blot as-
says (Fig. 4). The distribution of cells in G0/G1, S, and G2/M
phases contributing to the extracts prepared for analysis
was measured by flow cytometric analysis of parallel sam-
ples stained with propidium iodide (Fig. 4 
 
A
 
). Western
blot analysis confirmed that Myf5 protein levels are regu-
lated by progression through the cell cycle (Fig. 4 
 
B
 
, 
 
mid-
dle
 
). Moreover the observed variations in protein level are
largely independent of the level of Myf5 mRNA measured
(Fig. 4 
 
B
 
, 
 
bottom
 
), implying that the cell cycle–associated
fluctuations of Myf5 protein result from posttranscrip-
tional mechanisms. The level of transcription factor cJun
(Fig. 4 
 
B
 
, 
 
top
 
) does not show cell cycle regulation. The
variations seen in the level of Myf5 mRNA are slight:
quantification of the Northern blot shown in Fig. 4 
 
B
 
, after
PhosphorImager analysis (not shown), reveals a two-fold
difference between the highest level, in M phase cell ex-
tracts, and that in the unsynchronized population.
Figure 2. Expression pat-
terns of MyoD and Myf5 in
C2.7 cells are distinct. C2.7
cells in cultures undergoing
autonomous differentiation
were simultaneously stained
for Myf5 expression (green)
and MyoD expression (red).
Cultures prepared (as de-
scribed in Materials and
Methods) such that cells
were either still at the myo-
blast stage (A), or had under-
gone some fusion (B), were
selected for analysis by con-
focal microscopy. Bars, 10 mm.
Figure 3. Myf5 expression
varies with the cell cycle.
Anti-IGFII C2 cells were
synchronized by growth in
0.5% serum for 24 h (G0,
top) followed by 6 h stimula-
tion in 20% serum in the
presence of 2 mg/ml aphidi-
colin (G1, center) followed
by removal of aphidicolin for
6 h (S, bottom). Cells were
fixed and stained for Myf5
expression. The designation
of cell cycle phases in this fig-
ure is justified in Fig. 4 A. Bar,
10 mm. 
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We find that whereas Myf5 mRNA is downregulated in
G0 (Fig. 4 
 
B
 
, lane 
 
2
 
; and Montarras et al., 1996), the pro-
tein accumulates to a higher level in G0 than in the unsyn-
chronized population, but that this level falls as cells pass
through G1 (Fig. 4 
 
B
 
, lane 
 
3
 
). Myf5 protein accumulates
during S phase (Fig. 4 
 
B
 
, lanes 
 
4
 
 and 
 
5
 
). The most striking
discrepancy between the levels of message and protein oc-
curs in the population that is largely synchronized in M
phase (Fig. 4 
 
B
 
, lane 
 
6
 
). Here the message is most abun-
dant, but the Myf5 protein appears to be almost com-
pletely absent. Release of cells from the nocodazole block
allows completion of mitosis and resynthesis of Myf5 (Fig.
4 
 
B
 
, lane 
 
7
 
).
There is a population of cells that does not exit G0/G1
after serum deprivation (Fig. 4 
 
A
 
, sample 
 
6
 
), thus the fluc-
tuations in level of Myf5 may be underestimated by this
experiment.
Attempts to synchronize cells through mitosis without
use of nocodazole (i.e., by release of cells arrested at the
G1/S transition) were not successful. Thus it was necessary
to consider the possibility that nocodazole regulates the
level of Myf5 (but not those of cJun, cFos, Sp1; Fig. 4, 
 
B
 
and 
 
C
 
; and data not shown) by a mechanism that is not re-
lated to cell cycle arrest. We prepared separate fractions of
mitotic and nonmitotic cells from plates treated with no-
codazole for 6 h (time of treatment that had no effect on
the level of Myf5 in nonmitotic cells; Fig. 4 
 
B
 
, compare
lanes 
 
5
 
 and 
 
9
 
). In a typical experiment, the mitotic fraction
consisted of 90–95% cells containing condensed chromatin
as judged by propidium iodide labeling of ethanol-fixed
cells (not shown). Replated cells from the mitotic fraction
completed mitosis and showed a growth rate and differen-
tiation capacity identical to that of the nonmitotic fraction
(not shown). Extracts prepared from these fractions were
analyzed by immunoblot (Fig. 4 
 
C
 
). It was found that Myf5
is specifically absent from the mitotic fraction comprising
cells arrested in pro-metaphase. Since treatment of cells
with nocodazole has no effect on the level of Myf5 in non-
mitotic cells, it can be concluded that mitotic arrest is re-
sponsible for the disappearance of Myf5.
The observed appearance of a more slowly migrating
form of Sp1 in the mitotic fraction (Fig. 4 
 
C
 
, 
 
top
 
) is consis-
tent with the previously described phosphorylation of Sp1
in nocodazole-blocked HeLa cells (Martinez-Balbas et al.,
1995).
 
Myf5 Is Phosphorylated and Degraded at Mitosis
 
We investigated the possibility that the disappearance of
Myf5 is because of an increase in its rate of degradation as
cells pass into mitosis. ALLN is commonly used as an in-
hibitor of proteasome-mediated proteolysis, and was used
to treat cells prepared for mitotic shake-off for 2 h before
preparation of extracts. Extracts were analyzed by immu-
noblotting using antibodies raised against both the NH
 
2
 
-
terminal and COOH-terminal portions of Myf5 to confirm
that lack of detection of Myf5 in mitotic extracts was not
because of epitope masking or partial degradation of the
protein. The results are shown in Fig. 5 A. The disappear-
ance of Myf5 from mitotic cell extracts, observed with
both of the antibodies tested (Fig. 5 A, lanes 2 and 6), is
blocked in the presence of ALLN (Fig. 5 A, lanes 4 and 8).
Thus proteolysis of Myf5 is responsible for its disappear-
ance at mitosis, and this probably occurs via the ubiquitin–
proteasome pathway. However the specificity of ALLN
also extends to nonproteasome proteases such as calpain;
one of these could be involved in the degradation of Myf5.
Figure 4. Myf5 is regulated
by posttranscriptional mech-
anisms that are cell cycle–
dependent. (A and B) Syn-
chronized populations of
anti-IGFII C2 cells were pre-
pared either for propidium
iodide labeling and flow cy-
tometric analysis, or for pro-
tein analysis, or for RNA
analysis. Nonsynchronized
population (1). Cells grown
in medium containing 0.5%
FCS for 24 h (2); this was re-
placed with medium contain-
ing 20% FCS plus 1 mg/ml
aphidicolin (Sigma Chemical
Co.), for 6 h (3). Aphidicolin-
containing medium was re-
moved and replaced with
medium containing 20%
FCS, for 1 h (4), 6 h (5), and
16 h (8); or medium contain-
ing 20% FCS plus 200 ng/ml
nocodazole for 6 h (9) and 16 h
(6). Cells treated for 16 h
with nocodazole, washed, and
then replated in medium
containing 20% FCS, for 6 h
(7). (A) Analysis by flow cy-
tometry of DNA content of
samples 1–6. Propidium io-
dide content is in arbitrary
units and the vertical axis in-
dicates cell count (not to
scale). The distribution of
cell populations in these sam-
ples confirms the synchroni-
zation of cells from G1 (pro-
pidium iodide content
equivalent to 2 N DNA con-
tent) through S phase to mito-
sis (4 N DNA content). A cer-
tain fraction of cells seem to
be unable to exit G0, since
the 2 N population seen in
sample 6 is absent from cells
that have been treated with nocodazole without prior serum with-
drawal (not shown). (B) Analysis of Myf5 protein and mRNA in
extracts from synchronized cells. Immunoblot analyses used rab-
bit anti-Myf5 NH2-terminal antiserum, and mouse mAb against
cJun as a control. Myf5 mRNA levels measured by Northern blot
analysis were quantitated by use of a PhosphorImager and cor-
rected for the level of mRNA of ribosomal subunit S-26 (not
shown) to confirm that the variation of Myf5 mRNA in these ex-
tracts is low. (C) Proliferating anti-IGFII C2 cells treated for 6 h
with 200 ng/ml nocodazole were used to generate a mitotic frac-
tion (SO, shake-off fraction) and a nonmitotic fraction (Ad, ad-
herent). These were analyzed by immunoblotting for expression
of Myf5 (anti–NH2-terminal antiserum), cJun, and Sp1.The Journal of Cell Biology, Volume 140, 1998 116
The Myf5 protein detected in the presence of ALLN ex-
ists as a more slowly migrating form (Fig. 5 A, lanes 4 and
8), which is detected only in mitotic extracts. By treating
extracts shown in Fig. 5 A with alkaline phosphatase, we
investigated whether the shift in mobility of Myf5 in mi-
totic cells was because of phosphorylation of the protein
(Fig. 5 B). Phosphatase treatment of the ALLN-treated
mitotic shake-off extract did indeed reverse the shift in
mobility of Myf5 (Fig. 5 B, extract 8). Parallel treatment of
a mitotic shake-off extract confirms that there is no epi-
tope masking through phosphorylation of Myf5 in mitotic
cells (Fig. 5 B, extract 6). Both mitotic and nonmitotic
forms of Myf5 appear to be stable in the extracts used,
even at 378C (Fig. 5 B, panels 7 and 8).
These data strongly suggest that Myf5 undergoes phos-
phorylation by a mitosis-specific kinase(s), and that this
modified Myf5 is highly unstable in mitotic cells and is rap-
idly degraded, probably by a 26-S proteasome-dependent
mechanism.
MyoD Does Not Undergo Cell Cycle–dependent 
Variation in Expression
To investigate whether MyoD might be subject to similar
cell cycle regulation we have synchronized C2.7 cells by
suspension in methyl cellulose–containing medium for 48 h
as described in Milasincic et al. (1996). This leads to re-
versible arrest in G0 and extinction of MyoD expression
(Milasincic et al., 1996). MyoD is resynthesized on reat-
tachment of these cells but we have been unable to detect
any variation in the level of MyoD during the subsequent
cell cycle (data not shown). Moreover, analysis of the mi-
totic fraction from nocodazole-treated cultures of C2.7
cells reveals that MyoD is present in these cells (Fig. 6).
The migration of MyoD as a doublet in SDS–polyacryla-
mide gels has previously been ascribed to phosphorylation
of the slowly migrating form (Skapek et al., 1995). There is
an increase in the relative amount of the slowly migrating
form of MyoD in mitotic cells (Fig. 6, top right), this could
be the result of new phosphorylation of the protein, or of
preferential degradation of the faster migrating form dur-
ing mitosis. However, the total quantity of MyoD in mi-
totic cells does not appear to be significantly diminished,
whereas Myf5 has undergone complete destruction (Fig. 6,
bottom).
Discussion
The results presented in this paper show that expression of
the muscle determination factor Myf5 is associated with
proliferating myoblasts and tightly regulated by the cell
cycle.
We show that downregulation of Myf5 in C2 cells can
occur as early as the onset of differentiation, when cells
become myogenin-positive. Previous results obtained us-
ing primary muscle cell cultures (Smith et al., 1993) have
described the codetection of Myf5 with a differentiation
marker in myotubes and these authors conclude that the
different MRFs define different types of myoblast rather
than different stages of determination and differentiation.
We have examined Myf5 expression in mouse and human
primary myoblast cultures and found that the level of
Myf5 expression in differentiating cells is low compared to
that in surrounding myoblasts, although we can detect
Myf5 in some young myotubes (Pinset, C., D. Montarras,
and C. Lindon, unpublished observations).
It is possible that the sequence of events that occurs in
differentiating C2 cells represents the differentiation of a
subset of myoblasts in vivo. However our observations in
primary cultures are consistent with the conclusion that
strong expression of Myf5 (in contrast to that of MyoD) is
restricted to myoblasts in the proliferative state. This con-
clusion raises the possibility that the downregulation of
Myf5 could be requisite for the progress of differentiation.
In support of this idea, we have previously observed that
in myoblasts unable to undergo differentiation Myf5 ex-
pression is upregulated (Montarras et al., 1996).
We also show that Myf5 accumulates in S phase, and is
depleted in mitotic cells. Since Myf5 mRNA levels are not
affected by the cell cycle, the loss of Myf5 protein expres-
sion must be a posttranscriptional event. This is not a gen-
eral block in translation since the level of cJun (t1/2 5 90
min) is not affected even after prolonged nocodazole treat-
ment (24 h; data not shown). We have shown that the pro-
teolytic degradation of Myf5, most probably by the 26-S
proteasome, is responsible for its disappearance. How-
Figure 5. Myf5 undergoes destruction at mitosis after mitosis-
specific phosphorylation. (A) Mitotic and nonmitotic fractions
were prepared as described in Fig. 4 C but with the following ad-
ditions to cultures 2 h before shake-off: ALLN was added to a fi-
nal concentration of 0.1 mM from a stock in DMSO (1ALLN);
controls received an equivalent volume of DMSO (2ALLN). S0,
shake-off fraction (mitotic cells); Ad, adherent fraction (nonmi-
totic cells). (B) Three of the extracts analyzed in A (lanes 6, 7,
and 8) were incubated for 1 h at 378C with (phosphatase-treated)
or without (mock-treated) calf intestinal phosphatase (5 U/100 ml
extract; from Pharmacia Biotechnology Inc.) and analyzed by im-
munoblotting with the COOH-terminal antibody used in A
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ever, we have not excluded the possibility that a specific
arrest in translation of the Myf5 message contributes to
the downregulation of this factor at mitosis.
Although nocodazole artificially prolongs the time cells
spend in mitosis, the absence of any trace of Myf5 from
mitotic extracts leads us to conclude that this factor under-
goes complete destruction either at, or just before, entry
into mitosis. Proteolytic degradation follows a phosphory-
lation(s) specific to this phase of the cell cycle. Phosphory-
lation at mitosis has been documented for several tran-
scription factors. In some cases this has been described as
a mechanism for preventing DNA binding (Roberts et al.,
1991; Caelles et al., 1995), and in other cases has been shown
to correlate with dissociation of transcription factors from
condensed chromatin (Martinez-Balbas et al., 1995; Mu-
chardt et al., 1996). However, to our knowledge this is the
first description of the destruction of a transcription factor
at mitosis.
We have previously observed that high level expression
of Myf5 is incompatible with cellular proliferation in non-
transformed cells: Muscle cell lines derived from embry-
onic 10T1/2 fibroblasts transfected with Myf5 are found to
express the gene at a level severalfold lower than that seen
for any of the other MRF factors, and detectable only by
RT-PCR analysis (Auradé et al., 1994). In contrast, we find
that HeLa cells (which are transformed and not convert-
ible to the myogenic lineage) are able to express Myf5 in a
stable fashion at high levels (Lindon, C., unpublished ob-
servation). In addition, we note that the only established
muscle cell lines described that express high levels of Myf5
are those that have been chemically transformed (Braun
et al., 1989a). We propose that nontransformed, cycling
cells need to degrade Myf5 during each cell cycle to over-
come a negative effect of Myf5 on cell cycle progression,
and that this is the basis for the apparent toxicity of Myf5
overexpression.
Do Myf5 and MyoD play distinct roles in proliferating
myoblasts? The cell cycle–associated variation in Myf5
that we have described contributes to the heterogeneity of
Myf5 in proliferating myoblasts observed by immunofluo-
rescence. There is no clear correlation between the levels
of Myf5 and MyoD from cell to cell and we have been un-
able to detect cell cycle effects on MyoD levels present in
C2 cell extracts. Given the upregulation of MyoD ob-
served in differentiating myoblasts, it seems likely that the
accumulation of MyoD is incremental rather than cyclic,
and that above a certain threshold level cells become com-
mitted to differentiate in response to favorable conditions
(such as serum depletion).
Mechanisms by which cyclin D1 suppresses MyoD activ-
ity during the cell cycle have been described (Rao et al.,
1994; Skapek et al., 1995, 1996). Clearly there are addi-
tional mechanisms by which the cell cycle regulates the ac-
tivity of the myogenic bHLH factor family and it seems
likely that Myf5 functions in response to conditions dis-
tinct from those that induce the myogenic activity of MyoD.
We have previously observed that transcription of myf5
is highly sensitive to culture conditions and rapidly upreg-
ulated by agonists of the stress-activated protein kinases
(Auradé et al., 1997). Our finding that basal Myf5 levels
are very low or nonexistent in G1 and M phases suggests
that the induction of Myf5 during these phases of the cycle
could influence progress through the cell cycle and the
commitment to differentiation. We believe that the further
study of Myf5 functions and of its posttranscriptional regu-
lation will advance our understanding of the mechanisms
involved in determination.
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